FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)
Gastric Cancer
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring gastric cancer, oxaliplatin, irinotecan, sequential treatment
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed gastric cancer
- No prior chemotherapy for palliative setting
- ECOG PS <3
- Measurable lesion on CT
- adequate kidney function (CCr ≥ 40 ml/min)
- adequate liver function (Transaminase < 3 X upper normal value, Bilirubin < 2 mg%)
- adequate BM function (ANC > 1500/ul, platelet > 75000/ul)
- informed consent
Exclusion Criteria:
- other cancer history
- pregnant or breast feeding
- inadequate general condition for chemotherapy
- allergy to oxaliplatin or irinotecan
Sites / Locations
- Sung Yong Oh
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
IROX arm: FOLFIRI -> FOLFOX
OXIR arm: FOLFIRI -> FOLFOX
IROX arm: FOLFIRI -> FOLFOX FOLFOX REGIMEN D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr Every 2 weeks FOLFILI REGIMEN D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
OXIR arm: FOLFIRI -> FOLFOX FOLFOX REGIMEN D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr Every 2 weeks FOLFILI REGIMEN D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr